{
    "clinical_study": {
        "@rank": "159584", 
        "arm_group": [
            {
                "arm_group_label": "Candesartan", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis\n      upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and\n      cGMP pathway.\n\n      The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and\n      renal dysfunction will improve renal function with increased sodium excretion, glomerular\n      filtration rate and effective renal plasma flow and renal function reserve as compared to\n      the response of placebo-treated subjects."
        }, 
        "brief_title": "Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "\"Cardiorenal Syndrome (CRS)\"", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Left ventricular ejection fraction of equal or less than 40% assessed by\n             echocardiography, nuclear scan, MRI or left ventriculogram within the past 48 months.\n\n          -  Stable New York Heart Association (NYHA) class II and III symptoms as defined by: no\n             change in NYHA symptoms over the past 3 months, on stable doses of ACE inhibitor,\n             beta blocker, digoxin and furosemide over the last 4 weeks and no episode of\n             decompensated CHF over the past 6 months.\n\n          -  Calculated creatinine clearance of equal or less than 80 ml/min and greater than 20\n             ml/min, using the MDRD formula assessed within the past 48 months and a confirmatory\n             calculated creatinine clearance equal or less than 80 ml/min and greater than 20\n             ml/min at the time of enrollment.\n\n        Subjects who are already taking AT1 receptor blocker will be excluded.  Aldosterone\n        antagonist, antiarrhythmic medications and other vasodilators will be allowed; however,\n        all medications must be at stable doses 4 weeks prior to enrollment.  Subjects taking\n        nonsteroidal anti-inflammatory drugs (NSAIDs) except aspirin will not be able to increase\n        their medication dose for the duration of the study.  Subjects will be excluded if they\n        have had a prior diagnosis of intrinsic renal disease, including renal artery stenosis of\n        > 50%, or if they meet any one of the exclusion criteria listed below.\n\n        Exclusion Criteria:\n\n          -  Prior diagnosis of intrinsic renal diseases including renal artery stenosis of > 50%\n\n          -  Peritoneal or hemodialysis within 90 days or anticipation that dialysis or\n             ultrafiltration of any form will be required during the study period\n\n          -  Hospitalization for decompensated CHF during the past 6 months\n\n          -  Subjects that are taking AT1 receptor blockers\n\n          -  Myocardial infarction within 6 months of screening\n\n          -  Unstable angina within  6 months of screening, or any evidence of myocardial ischemia\n\n          -  Significant valvular stenosis, hypertrophic, restrictive or obstructive\n             cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy\n             proven active myocarditis\n\n          -  Severe congenital heart diseases\n\n          -  Sustained ventricular tachycardia or ventricular fibrillation within 14 days of\n             screening\n\n          -  Second or third degree heart block without a permanent cardiac pacemaker\n\n          -  Stroke within 3 months of screening, or other evidence of significantly compromised\n             CNS perfusion\n\n          -  ALT >1.5 times the upper limit of normal\n\n          -  Serum sodium of  < 125 mEq/dL or > 160 mEq/dL\n\n          -  Serum potassium of < 3.5 mEq/dL or > 5.7 mEq/dL\n\n          -  Serum digoxin level of > 2.0 ng/ml\n\n          -  Hemoglobin < 9 gm/dl\n\n          -  Other acute or chronic medical conditions or laboratory abnormality which may\n             increase the risks associated with study participation or may interfere with\n             interpretation of the data\n\n          -  Received an investigational drug within 1 month prior to dosing\n\n          -  Patients with an allergy to iodine.\n\n          -  Female subject who is pregnant or breastfeeding\n\n          -  In the opinion of the investigator, is unlikely to comply with the study protocol or\n             is unsuitable for any reasons"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678794", 
            "org_study_id": "09-003284", 
            "secondary_id": "1R01HL084155-01A2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Candesartan", 
                "description": "4 mg once a day up to 13 day.  dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated", 
                "intervention_name": "Candesartan", 
                "intervention_type": "Drug", 
                "other_name": "Atacand"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Candesartan", 
                "Candesartan cilexetil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic heart failure (CHF)", 
            "cardiac and renal dysfunction"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "harstad.lynn@mayo.edu", 
                "last_name": "Lynn Harstad", 
                "phone": "507-284-4838"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in Glomerular Filtration Rate (mL/min/1.73 m2)", 
                "safety_issue": "No", 
                "time_frame": "baseline to 3 months"
            }, 
            {
                "measure": "change in urinary Sodium excretion", 
                "safety_issue": "No", 
                "time_frame": "baseline to 4 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678794"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Horng Chen", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}